ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1423	National Cancer Institute	Html	en	Oral Cavity and Oropharyngeal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing cancer of the lip or mouth and about approaches that may help in the prevention of this disease.	large cohort study 0.376766 oral cavity accounts 0.552607 Papua New Guinea 0.380571 French Guiana 0.34684 United States 0.44201 age-adjusted incidence 0.362072 100,000 0.359624 areca nut. 0.346627 high alcohol intake 0.39156 epidemiologic studies 0.378316 oropharyngeal cancers 0.387229 5-year survival rate 0.495328 oropharyngeal cancer. 0.45765 personal history 0.348827 Human papillomavirus 0.350206 oral cavity cancer 0.797428 future primary cancer 0.407597 betel quid 0.499314 tobacco 0.395457 stage-specific survival rates 0.38041 important risk factor 0.379095 World Standard Population 0.382887 regional lymph node 0.379129 U.S. incidence 0.3611	worldwide incidence rate 0.411302 Squamous cell carcinoma 0.382371 risk factors 0.357771 elevated risk 0.400796 betel-quid chewing 0.354181 distinct diseases 0.351665 relative risk 0.346929 mortality rate 0.410597 common pharyngeal cancer. 0.386214 pharynx cancer 0.364625 persons 0.372394 Gutka chewing 0.349427 commonly available forms 0.391505 smokeless tobacco 0.374103 oral mucosal 0.411667 high risk 0.355532 neck region 0.347305 oral cavity 0.982405 oropharyngeal cancer 0.482897 mortality estimates 0.39101 added tobacco 0.357539 betel leaf 0.365996 mortality rates 0.364344	CLICK HERE
1616	National Cancer Institute	Html	null	Cardiopulmonary Syndromes (PDQ®)–Patient Version	Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.			CLICK HERE
1769	National Cancer Institute	Html	es	Humo de tabaco en el ambiente y el cáncer	Hoja informativa que resume los estudios sobre los efectos para la salud de la exposición al humo de tabaco en el ambiente.	Protección Ambiental 0.571939 única forma 0.552366 organiza reuniones 0.546237 vías respiratorias 0.568775	Estados Unidos 0.886156 Healthy People 0.776058 ambiente causa 0.925234 programa nacional 0.64248	CLICK HERE
1818	National Cancer Institute	Html	es	Tratamiento del cáncer de paratiroides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de paratiroides.	Parathyroid carcinoma versus 0.314395 Lippincott Williams 0.313221 interdisciplinary management 0.305907 Lumachi F 0.309431 carcinoma with tc-99m 0.305998 Functioning parathyroid carcinoma 0.307209 Favia G 0.309942 American Cancer Society 0.316114 Cancer Data Base 0.316291 metastasis from parathyroid 0.30974 postoperative parathyroid carcinoma 0.307215 Fleming ID 0.306345 Hundahl SA 0.306222 Data Base Report 0.311266 DeVita VT Jr 0.324372 Radiat Oncol Biol 0.307199 glándulas paratiroides 0.306363 from parathyroid carcinoma 0.319948 parathyroid tumors 0.321669 Clinical review 0.314388 parathyroid carcinoma 0.98314 Prognostic factors 0.306954 Sandelin K 0.34021 metastatic parathyroid carcinoma 0.313321 Bondeson L 0.30997	Rosenberg SA 0.31229 Clin Endocrinol Metab 0.394458 Lawrence TS 0.312691 National Cancer 0.333111 parathyroid carcinoma with 0.31437 parathyroid adenoma 0.30731 Bilezikian JP 0.306387 carcinoma paratiroideo 0.32174 National Cancer Database 0.307384 primary hyperparathyroidism 0.309819 Surg Oncol 0.319122 Busaidy NL 0.306079 National Cancer Data 0.316413 carcinoma versus parathyroid 0.314395 Fremgen AM 0.306349 Auer G 0.3065 9th ed 0.313566 pulmonary metastasis from 0.306768 Kebebew E 0.312769 Oncol Biol Phys 0.30731 Surgeons Commission 0.306833 Princess Margaret Hospital 0.306413 recurrent parathyroid carcinoma 0.307247 parathyroid carcinoma treated 0.330169	CLICK HERE
1862	National Cancer Institute	Html	es	Tratamiento del cáncer de uretra (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de uretra.	urethral tumors 0.342422 secciones distal 0.323073 Lippincott Williams 0.35647 Lin DW 0.322871 papillomaviruses with carcinomas 0.32226 transitional cell carcinoma 0.357652 Ta Carcinoma 0.32924 Gomella LG 0.359219 urethral tumor involvement 0.329567 7th ed 0.322172 Coordinated chemoradiation therapy 0.336249 Instituto Nacional 0.32668 DeVita VT Jr 0.40337 urethra with chemotherapy 0.34093 chemoradiation therapy with 0.337618 Karnes RJ 0.33747 plus infusional high 0.33117 Porter MP 0.322353 Rosenberg SA 0.353321 Male urethral carcinoma 0.339582 Breau RH 0.33767 tercio distal 0.368197 Lawrence TS 0.353966 urethral carcinoma 0.638147 United States 0.321915	End Results 0.324443 Urol Clin North 0.656789 Koontz BF 0.336415 primary urethral carcinoma 0.381596 lesiones tis 0.323889 Cancer Staging Manual 0.353458 lesiones t3 0.324367 radiation oncology 0.341092 lesiones t1 0.339652 Female urethral carcinoma 0.338979 primary invasive carcinoma 0.362458 Lee WR 0.334415 uretra distal 0.976805 Swartz MA 0.321742 9th ed 0.357004 Clin North Am 0.654236 Successful treatment 0.323556 numerosas glándulas 0.322763 Lightner DJ 0.335736 tis pd carcinoma 0.335113 Zhang ZF 0.322598 Tis Carcinoma 0.330085 metastatic urothelial carcinoma 0.358216 AJCC Cancer Staging 0.35514	CLICK HERE
1904	National Cancer Institute	Html	es	Tratamiento del cáncer epitelial de ovario, de trompa de Falopio y primario de peritoneo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer epitelial de ovario, de trompa de Falopio y primario de peritoneo.	siguientes procedimientos 0.423688 quimioterapia ip 0.416839 estadios ii 0.409427 siguientes aspectos 0.416771 causa hinchazón 0.412974 Ecografía abdominal 0.413715 rayos x 0.41264 estadio ic 0.511392 estadio ivb 0.503452 estadio ib 0.512383 estadio ia 0.511445 enlace drugs approved 0.449365 Fallopian Tube 0.428306 ondas sonoras 0.413458 estadio iva 0.501667 National Cancer Institute 0.410523 Primary Peritoneal Cancer 0.449696 siguientes riesgos 0.40878 realidad células 0.424697 siguientes tratamientos 0.411661 Instituto Nacional 0.43725 estadio iiia 0.506125	PDQ Tratamiento 0.420853 estadio iiic 0.505194 ganglios linfáticos detrás 0.603433 estadio iiib 0.505868 estadio iia 0.510869 estadio iib 0.511005 Physician Data Query 0.437199 or primary peritoneal 0.450381 estadio iii 0.551718 peritoneo causa efectos 0.460442 siguientes situaciones 0.416252 cuello uterino 0.944087 ovario.ampliar anatomía 0.415019 PDQ Prevención 0.426006 histerectomía laparoscópica total.Ampliar 0.422039 siguientes enlaces 0.409849 ecografía transvaginal.Ampliar 0.413879 histerectomía abdominal 0.414317 genes brca1 0.412481 siguientes sumarios 0.425477 siguientes pruebas 0.420302	CLICK HERE
1919	National Cancer Institute	Html	es	Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos.	pequeñas incisiones 0.360209 Cirujano oncólogo 0.35403 Clinic Liver Cancer 0.895614 siguientes procedimientos 0.409083 siguientes aspectos 0.386863 pequeña cantidad 0.337477 tratamiento causa 0.413554 siguientes métodos 0.411504 siguientes especialistas 0.376622 rayos x 0.47678 imagen tridimensional 3-D 0.372363 lesiones duraderas 0.36475 sustancias dañinas 0.379531 cuerpo usa 0.466772 ondas sonoras 0.366833	triple fase 0.491781 National Cancer Institute 0.334891 siguientes riesgos 0.332851 sección superior derecha 0.425641 Instituto Nacional 0.432945 siguientes grupos 0.397061 PDQ Tratamiento 0.382467 siguientes puntos 0.412752 estadificación barcelona clinic 0.916026 hepatitis c 0.503388 Drugs Approved 0.34614 Physician Data Query 0.434214 Barcelona Clinic Liver 0.903635 pequeña incisión 0.343621 siguientes enlaces 0.343192	CLICK HERE
2032	National Cancer Institute	Html	es	Exámenes de detección del cáncer de próstata (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de próstata.	or watchful waiting 0.527761 Prostate Cancer Group-4 0.536467 Koyama T 0.514342 estudio erspc 0.525762 Sin embargo 0.633101 Resnick MJ 0.514745 países cuáles factores 0.523397 detección versus 0.572904 Holmberg L 0.514356 ensayo plco 0.516954 Swedish Cancer Registry 0.524495 Ahmed HU 0.514521 jurisdicciones europeas colaboradoras 0.519184 Preventive Services Task 0.58607 Ovarian Cancer Screening 0.580102 consiguiente tratamiento 0.524752 Croswell JM 0.515275 estudio prostate testing 0.532458 Estados Unidos 0.630717 centro göteborg 0.570246 siguientes tasas 0.517703 Prostate Cancer Prevention 0.525333 PSA rutinarias 0.626469 FJ Jr 0.514192 evolución natural benigna 0.523168	centro sueco göteborg 0.523946 trascendencia clínica 0.542862 Lancet Oncol 0.516366 Eur Urol 0.51628 End Results 0.514418 Loeb S 0.514034 Scandinavian Prostate Cancer 0.583772 seguimiento diagnóstico 0.518794 Gen Intern Med 0.526679 lesiones prostáticas benignas 0.525347 radical prostatectomy 0.520653 Países Bajos 0.556513 Fan KH 0.51463 edad promedio 0.515679 Chou R 0.514768 PDQ Tratamiento 0.51809 European Randomized Study 0.573324 Intern Med 0.549412 Steineck G 0.514536 Services Task Force 0.584434 prostate cancer 0.738954 datos probatorios 0.915311 Prostate Intervention Versus 0.524636 Cancer Screening Trial 0.580497	CLICK HERE
3669	National Cancer Institute	Html	en	Hormone Replacement Therapy May Improve Survival for Women with Ovarian Cancer	The randomized, controlled Adjuvant Hormone Therapy trial was launched in 1990 to assess the effects of estrogen-alone hormone replacement therapy in women treated for epithelial ovarian cancer.	cancer prevention trials 0.416255 Rosalind A. Eeles 0.411778 surgical treatment 0.379516 estrogen-alone hormone replacement 0.439159 HRT 0.650737 control group 0.489038 HRT group 0.449172 ovarian function 0.415733 menopausal symptoms 0.542367 relapse-free survival 0.465056 Cancer Therapy Evaluation 0.421244 overall survival 0.581691 ovarian estrogen 0.432665 ovarian cancer 0.928941 ovarian cancer experience 0.492272 patients 0.45695 randomized clinical trial 0.43176 Elise C. Kohn 0.397302 adjuvant therapy 0.381362 standard treatment options 0.433426 median estimated time 0.405984 main secondary endpoint 0.410696 survival outcomes 0.37806 hormone therapy group 0.578064 mean overall survival 0.423556	potentially relevant factors 0.394794 hormone replacement therapy 0.634279 Hormone Therapy trial 0.447307 hormone therapy groups 0.42905 ovarian cancer treatment 0.476999 treatment groups 0.365534 women 0.520693 mean relapse-free survival 0.417235 random assignment 0.405372 comfortable offering patients 0.408947 additional health benefits 0.409837 adverse health effects 0.418883 Cancer Research 0.418301 severe menopausal symptoms 0.511618 epithelial ovarian cancer 0.775578 postmenopausal women 0.378934 trial results 0.36603 breast cancer 0.41792 transient ischemic attack 0.398107 treatment effects 0.367465 study authors 0.552833 Premenopausal women 0.389334 similar survival 0.379958 statistically significant differences 0.397215	CLICK HERE
16707	National Cancer Institute	Html	en	Aiming to Prevent Hereditary Cancers, Researchers Focus on Lynch Syndrome	An NCI research update article about a workshop to discuss new strategies for preventing hereditary cancers by using Lynch syndrome as a model.	diverse health care 0.453631 microsatellite instability 0.464772 Lynch syndrome carriers 0.517928 Dr. Umar 0.488743 individuals 0.536924 medical care involve 0.455237 new strategies 0.449549 mismatch repair genes 0.448736 Cancer Family Registry 0.46728 health care delivery 0.494388 cancer syndrome 0.478908 cancer syndromes 0.492489 early detection 0.47326 colorectal cancer 0.560507 cancer predisposition genes 0.467221 workshop 0.449162 certain cancers 0.476738 patients 0.457938 University Medical Center 0.449045 primary care physicians 0.529844 health care settings 0.476681 care delivery research 0.454487 high risk 0.449685 NCI launch projects 0.449436 Fight Colorectal Cancer 0.471174	additional cancer-related genes 0.448536 appropriate follow-up care 0.45773 model genetic disease 0.45275 demonstration project 0.47113 regular cancer screening 0.460711 genetic counseling 0.467826 Dr. Helzlsouer 0.48663 short-term cancer prevention 0.47054 Cancer MoonshotSM Blue 0.473627 Cancers Research Group 0.457769 ovarian syndrome 0.449875 health care 0.524132 Lynch syndrome 0.908406 colorectal cancer incidence 0.482957 Blue Ribbon Panel 0.624264 universal tumor testing 0.448868 early-onset colorectal cancer 0.482131 hereditary cancers 0.472304 Lynch syndrome-associated tumors 0.502642 Lynch syndrome testing 0.526531 follow-up medical care 0.536245 genetic testing 0.5207 different health care 0.454741 cancer 0.591093	CLICK HERE